about
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasmsmTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial.Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia veraPreclinical models for drug selection in myeloproliferative neoplasms.Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients.Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis.Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value.Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis.Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation.Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyureaRole of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosisCalreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasmsNo role for CXCL12–G801A polymorphism in the development of extramedullary disease in acute myeloid leukemiaNanoR: A user-friendly R package to analyze and compare nanopore sequencing dataCharacteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasmsFamilial dominant epilepsy and mild pachygyria associated with a constitutional LIS1 mutationCalreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutantsNano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data
P50
Q33982315-09E0CE73-43F0-49E7-B709-57BAC8F1DBA1Q34575726-845AC8F2-3162-4B4F-98B0-9291B75BEB1BQ35244917-29FA5835-4063-4294-8437-BBB84F63D747Q36003480-9982F5B5-C9E9-47AC-9497-ED4802724122Q37406784-29CFB0F8-069C-46B2-9794-9EAA0DE64840Q38154517-FE751C6C-D18B-4243-804D-9DEA0B78A471Q38167432-4B29640F-2D3A-440C-94F7-65C4726E7F7BQ38660742-AFCDDC82-888E-4EAE-A92C-40C3389A3344Q38669568-A256E8F1-9D5C-48E8-A9D9-2602E3B04BD0Q42870482-46CB187A-D7C2-4DED-8776-DFCEEB462B36Q47140652-3C8C34E6-0044-42ED-AC48-E19D44DB24FAQ47274508-6271EB39-E373-4D10-AB11-7A71E34FA35AQ59329603-DE69E934-F078-404A-BA5B-10F1FB3C7257Q59799223-3BBDC5A5-07D5-4CFE-B246-985BE2AA9F70Q61050080-79A690D5-2327-4A9A-AD4E-33E178EDDC87Q61050104-418D9492-B2E4-4F9E-A722-B995B87046EBQ64060998-D18B5A22-3E0B-4D5D-A950-E08D06A28B3EQ90978109-25C288C3-81E0-49FA-B07A-AFA8FD96A54DQ91137500-376E6C1C-303B-40E6-896B-C232EB32A934Q92092554-E8E09514-7F37-4934-BB5F-BEC6B5D988BFQ92865088-A9B830BC-477C-49B3-A2BA-B52068AAE660
P50
description
researcher ORCID ID = 0000-0002-9328-3948
@en
name
Niccolò Bartalucci
@ast
Niccolò Bartalucci
@en
Niccolò Bartalucci
@nl
type
label
Niccolò Bartalucci
@ast
Niccolò Bartalucci
@en
Niccolò Bartalucci
@nl
prefLabel
Niccolò Bartalucci
@ast
Niccolò Bartalucci
@en
Niccolò Bartalucci
@nl
P31
P496
0000-0002-9328-3948